AU Patent

AU2010201263B8 — Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding

Assigned to Scripps Research Institute · Expires 2013-04-18 · 13y expired

What this patent protects

A method of treating a transthyretin amyloid disease, the method comprising orally administering 250 mg of 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid twice per 5 day to a subject diagnosed as having a transthyretin amyloid disease.

USPTO Abstract

A method of treating a transthyretin amyloid disease, the method comprising orally administering 250 mg of 2',4'-difluoro-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid twice per 5 day to a subject diagnosed as having a transthyretin amyloid disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010201263B8
Jurisdiction
AU
Classification
—
Expires
2013-04-18
Drug substance claim
No
Drug product claim
No
Assignee
Scripps Research Institute
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.